NF2 and neoplasm: The tumor suppressor NF2 (merlin), which has emerged as a late event in the progression of PM [37,48] is frequently mutated across all subtypes, but some studies suggest a slightly higher prevalence in non-epithelioid tumors, aligning with the observation that Hippo pathway disruption can drive a more aggressive mesenchymal phenotype [37,38].